MEPSGEN US, Inc., a global innovator in drug delivery system platforms, announced the launch of NanoCalibur Mini, an automated system for small-volume nanoparticle formulation designed for early-stage drug discovery and development.

Nanoparticles are delivery vehicles that carry therapeutic payloads to target sites in the body, and they are central to next-generation modalities such as mRNA and gene therapies. Early-stage research requires repeated testing of many raw materials and process conditions, so the ability to generate fast, consistent results from limited material is essential.

NanoCalibur Mini formulates lipid nanoparticles (LNPs) and polymeric nanoparticles at volumes of 0.1–3 mL. Built on MEPSGEN's proprietary microfluidic technology, it delivers precise, stable microfluidic flow control for rapid and highly reproducible formulation. Researchers can choose between two single-use microfluidic cartridges, 0.1–0.4 mL and 0.4–3 mL, to match their application, from early formulation screening through a range of preclinical studies. By enabling many formulation conditions to be tested quickly with minimal material, Mini helps accelerate development timelines while reducing reagent consumption and experimental costs.

With the addition of Mini, the NanoCalibur Series now spans four systems (Mini, Lab, Pro, and GMP), allowing customers to select the right platform for their development stage and production scale.

The defining feature of the series is a consistent formulation environment at every scale. NanoCalibur Mini to Lab and to GMP uses the same microfluidic mixing pattern, with the same structure and dimensions. Rather than redesigning the mixer or changing the formulation conditions as production grows, NanoCalibur increases throughput by parallelizing identical mixing units. This design is intended to reduce the need for process re-optimization during scale-up and technology transfer, while preserving nanoparticle quality and batch-to-batch reproducibility.